«We thought it would be the next
big blockbuster drug for weight loss.»
Not exact matches
COPENHAGEN, April 10 Genmab plans to own a
bigger share of
drugs in its early - stage pipeline as Europe's
biggest biotechnology company prepares to reduce its reliance on a
blockbuster cancer
drug, marketed by partner Johnson & Johnson.
As
big pharmaceutical companies find that the patents for some of their
blockbuster drugs are expiring, they are desperately reaching out to replenish their
drug pipelines.
As the pharmaceutical industry's
blockbuster drugs fall off the patent cliff, with precious few
drugs in the pipeline to replace them, there are signs that
big pharma could turn more of its attention to biologically derived medicines.
As well, pharmaceutical companies are looking for new ways to address their two - pronged pipeline problem: many
big - name
blockbuster drugs will soon lose their patents and, perhaps more important, there is a dearth of new
blockbusters headed to the market.
Big Pharma's focus on
blockbuster cancer
drugs squeezes out research into potential treatments that are more affordable.
Knowing this,
Big Pharma has tried to make big bucks with a blockbuster weight loss drug, but their efforts have been a disast
Big Pharma has tried to make
big bucks with a blockbuster weight loss drug, but their efforts have been a disast
big bucks with a
blockbuster weight loss
drug, but their efforts have been a disaster.